Prostate adenocarcinoma in men younger than 50 years. A retrospective review of 151 patients

• Published in: Cancer Vol. 74; no. 6; pp. 1768 - 1777
• Main Authors: Aprikian, Armen G., Zhang, Zuo‐Feng, Fair, William R.
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc., A Wiley Company 15.09.1994; Wiley-Liss
• Subjects: Adult; age; Age Factors; Biological and medical sciences; epidemiology; Family Health; Humans; Lymphatic Metastasis; Male; Medical sciences; Middle Aged; Multivariate Analysis; Neoplasm Staging; Nephrology. Urinary tract diseases; Prognosis; Prostate - pathology; prostate cancer; Prostatic Neoplasms - complications; Prostatic Neoplasms - ethnology; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; race; Retrospective Studies; Survival Analysis; symptomatology; Time Factors; Tumors of the urinary system; Urinary tract. Prostate gland; young; United States; North America; America; Human; Adenocarcinoma; Histological grading; Urinary system disease; Prognosis; Malignant tumor; Prostatic disease; Epidemiology; Retrospective; Clinical stage; Young adult; Race; Male genital diseases; Prostate; Age
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/1097-0142(19940915)74:6<1768::AID-CNCR2820740620>3.0.CO;2-9

Background. Prostate adenocarcinoma is predominantly a disease of older men. Males younger than 50 years account for 1% of all patients with prostate cancer. The authors retrospectively examined cases of prostate adenocarcinoma in patients younger than 50 years of age to determine the natural history and prognosis of this malignancy in the younger population. Methods. The medical records of 151 patients were reviewed, with particular attention to age and year at diagnosis, race, symptoms at presentation, family history of prostate cancer, histologic grade, clinical and pathologic stage, treatment modality, and clinical outcome. Results. Univariate analyses demonstrated a significant correlation between higher disease stage (P = 0.0001), higher tumor grade (P = 0.0001), earlier year of diagnosis (P = 0.01), symptoms at presentation (P = 0.0001), and race (P = 0.01) with shorter disease‐specific survival. However, multivariate analysis revealed that only stage and grade were statistically significant predictors for poor prognosis after controlling for other variables. With a one‐unit increase of stage or grade, the risk of death from disease increases 2.2 or 1.9 times, respectively. Conclusion. These data suggest that patients younger than 50 years with prostate cancer present with similar symptomatology, histologic grade, and disease stage as the older population. Patients with disease confined to the prostate have a relatively good disease‐specific survival but remain at risk for death even 15 years after diagnosis When carcinoma escapes the confines of the prostate, the prognosis is uniformly poor.